Viridian Therapeutics, Inc. VRDN
25.15 USD -0.15 (-0.59%)
At closeNov 3, 2026, 4:30 PM EST
25.15 0.00 0.00%
After hours · Nov 3, 4:30 PM ET
24.52 Day range 26.21
13.18 52-week range 34.29
- YTD
- -19.18%
- 1 year
- +8.64%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 36.20 +43.9% upside
Now 25.15
- Target (low)
- 22.00
- Target (mean)
- 36.20
- Target (high)
- 50.00
Ratings (0m) 17 17 buy · 0 hold · 0 sell
- Strong buy3
- Buy14
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
- 3 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.02 | -1.26 – -0.78228 | -0.34 | -200.3% | 4.72M | -93.3% | 12 |
| Next quarter | -0.94748 | -1.21 – -0.70979 | -1.08 | +12.3% | 19.18M | +14427.6% | 12 |
| Current year | -3.92 | -4.60 – -3.41 | -3.32 | -18.2% | 24.30M | -65.7% | 13 |
| Next year | -2.71 | -4.10 – -1.70 | -3.92 | +30.9% | 237.80M | +878.4% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 30, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 30, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jun 30, 2026 | Needham | Maintained | Buy | Buy |
| Jun 29, 2026 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Jun 29, 2026 | Needham | Reiterated | Buy | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 5, 2026 | Needham | Reiterated | Buy | Buy |
| Apr 21, 2026 | Truist Securities | Maintained | Buy | Buy |
| Apr 8, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 7, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Apr 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 2, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Mar 31, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 31, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 30, 2026 | Needham | Maintained | Buy | Buy |
| Mar 11, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 27, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 4, 2026 | Needham | Reiterated | Buy | Buy |
| Feb 3, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 8, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 7, 2026 | UBS | Initiated | — | Buy |
| Dec 23, 2025 | Needham | Maintained | Buy | Buy |
| Dec 10, 2025 | Wedbush | Maintained | Outperform | Outperform |